Automation technology will play a key role in transforming labour-intensive regulatory processes in life sciences, but is AI being oversold by business process delivery partners? Alan White, CEO of Arriello, warns that focussed application is essential to delivering results.
AI
It won’t be long before the pharma and biotech industries are routinely deploying AI and machine learning to transform the pace and productivity of routine regulatory processes, according to Deloitte. It suggests that, by 2022, automated writing of clinical study reports will be happening as standard, using natural language processing - industrialising the conversion of structured study data into text narratives. Meanwhile leading firms will have automated up to 95% of regulatory filing, saving up to a year in their launch cycle.
Yet, there may be a risk that the promise of AI is being overstated, misleading life sciences firms to expect more dramatic results than they may actually experience.